For CHS matters:
Belinda Crist: Executive Assistant
Email: belinda.crist@unisa.edu.au
Phone: 08 830 22100
For CRI matters:
Kate Doyle: Institute Officer
Phone: 08 830 22648
Email: Kate.Doyle@unisa.edu.au
After a PhD and post-doctoral training in Manchester, Alan spent a period at the University of Washington before returning to the UK to focus on cancer therapy and the role of pharmacokinetics and pharmacology more generally. In Newcastle upon Tyne he established an internationally-recognised group working on the pharmacology of drugs in early phase clinical trials, pharmacology in children with cancer and pharmacogenetics.
He was instrumental in implementing quality control standards for academic-led studies in the UK, in conjunction with Cancer Research UK and the MHRA, and led an EU-funded international study on off-patent medicines in children. Alan also founded an online MSc course in Oncology and Palliative care that provided... Read more
About me
After a PhD and post-doctoral training in Manchester, Alan spent a period at the University of Washington before returning to the UK to focus on cancer therapy and the role of pharmacokinetics and pharmacology more generally. In Newcastle upon Tyne he established an internationally-recognised group working on the pharmacology of drugs in early phase clinical trials, pharmacology in children with cancer and pharmacogenetics.
He was instrumental in implementing quality control standards for academic-led studies in the UK, in conjunction with Cancer Research UK and the MHRA, and led an EU-funded international study on off-patent medicines in children. Alan also founded an online MSc course in Oncology and Palliative care that provided the model for online teaching at the University of Newcastle and led training workshops for clinicians and nurses on the principles of cancer pharmacology.
Moving to Sydney in 2014, he continued these interests, establishing links with the Melanoma Institute of Australia, Westmead Hospital and the Children’s Cancer Institute. Alan has published more than 150 peer-reviewed articles, in addition to reviews and book chapters and has supervised over 30 post-graduate students and clinical fellows.
Alan was appointed Head of School, Pharmacy and Medical Sciences at UniSA in July 2018 and became Dean of Research, Clinical and Health Sciences in April 2020.
About me
Doctor of Philosophy University of Manchester
Bachelor of Science (Honours) University of Manchester
Research
Research since 2008 is shown below. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2020 |
Open access
4
2
1
|
2020 |
1
1
4
|
2020 |
Open access
1
|
2020 |
1
1
|
2020 |
1
1
2
|
2020 |
|
2019 |
5
5
|
2019 |
Open access
4
3
4
|
2019 |
Open access
3
3
1
|
2019 |
2
2
3
|
2019 |
1
|
2018 |
Open access
1
|
2018 |
Open access
3
3
2
|
2017 |
66
58
3
|
2017 |
Open access
5
5
|
2017 |
Open access
3
4
2
|
2017 |
6
5
|
2017 |
Open access
6
7
|
2017 |
4
4
|
2017 |
Open access
7
8
1
|
2017 |
Open access
2
2
|
2016 |
7
5
1
|
2016 |
Open access
23
22
1
|
2016 |
Open access
85
82
16
|
2016 |
10
13
|
2016 |
Open access
19
18
2
|
2016 |
Open access
18
19
1
|
2016 |
Open access
4
4
|
2016 |
Open access
12
12
4
|
2016 |
Open access
3
|
2016 |
2
2
1
|
2016 |
40
45
4
|
2016 |
5
4
4
|
2016 |
Open access
21
19
2
|
2016 |
Open access
14
13
1
|
2015 |
Open access
27
32
3
|
2015 |
Open access
25
26
2
|
2015 |
Open access
41
39
|
2015 |
13
11
1
|
2014 |
Open access
24
20
1
|
2014 |
25
25
|
2014 |
2
2
2
|
2014 |
Open access
25
25
|
2014 |
Open access
25
25
8
|
2013 |
8
8
|
2013 |
Open access
25
26
|
2013 |
22
22
|
2013 |
Open access
28
23
4
|
2012 |
10
10
|
2012 |
5
5
2
|
2012 |
17
13
|
2011 |
15
11
|
2011 |
Open access
11
9
|
2011 |
25
24
|
2011 |
26
24
4
|
2011 |
12
12
4
|
2011 |
Open access
272
251
4
|
2011 |
Open access
39
36
|
2010 |
Open access
111
100
|
2010 |
Open access
38
39
|
2010 |
21
19
|
2010 |
22
21
|
2010 |
11
11
|
2009 |
13
11
|
2009 |
Open access
67
61
|
2009 |
17
18
|
2009 |
14
16
|
2009 |
Open access
77
81
|
2008 |
Open access
8
8
|
2008 |
21
19
|
2008 |
Open access
302
286
|
2008 |
Open access
14
12
|
External engagement & recognition
Organisation | Country |
---|---|
Academic Medical Centre | NETHERLANDS |
Aix-Marseille University | FRANCE |
Alder Hey Children's NHS Foundation Trust | UNITED KINGDOM |
Astex Therapeutics | UNITED STATES |
Beatson West of Scotland Cancer Centre | UNITED KINGDOM |
Birmingham Children's Hospital | UNITED KINGDOM |
Brigham and Women's Hospital | UNITED STATES |
Bristol Royal Hospital for Children | UNITED KINGDOM |
Bristol-Myers Squibb, UK | UNITED STATES |
Bristol-Myers Squibb, US | AUSTRALIA |
Calvary Mater Hospital | AUSTRALIA |
Cancer Research Uk | UNITED KINGDOM |
Cantonal Hospital, St. Gallen | SWITZERLAND |
Childrens Hospital of Philadelphia | UNITED STATES |
Chris O'Brien Lifehouse | AUSTRALIA |
CNIO | SPAIN |
Concord Repatriation General Hospital | AUSTRALIA |
Dankook University | KOREA, REPUBLIC OF (SOUTH) |
Derriford Hospital | UNITED KINGDOM |
Dipartimento di Pediatria, Padua | ITALY |
Emma Children's Hospital/AMC | NETHERLANDS |
EORTC Headquarters | BELGIUM |
European Medicines Agency | UNITED KINGDOM |
Freeman Hospital | UNITED STATES |
Freeman Hospital, Newcastle-upon-Tyne Hospitals | UNITED KINGDOM |
Great North Children's Hospital | UNITED KINGDOM |
Great Ormond Street Hospital for Children NHS Trust | UNITED KINGDOM |
Gustave Roussy | FRANCE |
Gustave-Roussy | FRANCE |
Hospital Timone | FRANCE |
Hunter Medical Research Institute, Australia | AUSTRALIA |
Indian Institute of Technology, Kharagpur | INDIA |
Inserm UMR | FRANCE |
Institut Gustave Roussy | FRANCE |
Institute of Cancer Research | UNITED KINGDOM |
Istituto di Ricerche Farmacologiche Mario Negri | ITALY |
Leeds General Infirmary | UNITED KINGDOM |
Leiden Academic Centre for Drug Research | NETHERLANDS |
Leiden University | NETHERLANDS |
Mayo Clinic | UNITED STATES |
Melanoma Institute Australia | AUSTRALIA |
Merck Research Laboratories | UNITED STATES |
MethylGene | CANADA |
Metrum Institute | UNITED STATES |
NanoCarrier | JAPAN |
National Cancer Center Hospital East | UNITED STATES |
Netherlands Cancer Institute | NETHERLANDS |
Newcastle Freeman Hospital | UNITED KINGDOM |
Newcastle University, United Kingdom | UNITED KINGDOM |
Newcastle upon Tyne Hospitals NHS Foundation Trust | UNITED KINGDOM |
Northern Centre for Cancer Care | UNITED KINGDOM |
Northern Centre for Cancer Care, Freeman Hospital | UNITED KINGDOM |
Northern Institute for Cancer Research | UNITED KINGDOM |
Nottingham City Hospital | UNITED KINGDOM |
Nottingham University Hospitals NHS Trust | UNITED KINGDOM |
Paul Sabatier University | FRANCE |
Pennsylvania State University | UNITED STATES |
Pfizer Australia Pty Ltd | AUSTRALIA |
Pfizer Global Research and Development | UNITED STATES |
Pfizer Limited, UK | UNITED KINGDOM |
Pfizer Oncology | UNITED STATES |
Princess Margaret Hospital | TUVALU |
Queen Mary University of London | UNITED KINGDOM |
Queen's University Belfast | UNITED KINGDOM |
Royal Marsden Hospital | UNITED KINGDOM |
Royal Victoria Infirmary | UNITED KINGDOM |
Saint Anna Children's Hospital | AUSTRIA |
Simcyp Limited (a Certara Company) | UNITED KINGDOM |
St James's University Hospital | UNITED KINGDOM |
St. James's Hospital | UNITED STATES |
Tata Memorial Hospital | INDIA |
Texas Children's Cancer center | UNITED STATES |
The Royal Marsden NHS Foundation Trust | UNITED KINGDOM |
UCL Cancer Institute | UNITED KINGDOM |
Université Paris-Saclay | FRANCE |
University College Hospital | UNITED KINGDOM |
University College London | UNITED KINGDOM |
University Hospital Muenster | GERMANY |
University Institute Cancer Toulouse Oncopole | FRANCE |
University of Adelaide | AUSTRALIA |
University of Birmingham | UNITED KINGDOM |
University of Cologne | GERMANY |
University of Durham | UNITED KINGDOM |
University of Glasgow | UNITED KINGDOM |
University of Malawi | MALAWI |
University of Manchester | UNITED KINGDOM |
University of Melbourne | AUSTRALIA |
University of Minnesota, Twin Cities | UNITED STATES |
University of Muenster | GERMANY |
University of New South Wales | AUSTRALIA |
University of Newcastle | AUSTRALIA |
University of Nottingham | UNITED KINGDOM |
University of Oxford | UNITED KINGDOM |
University of Padova | ITALY |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Technology Sydney | AUSTRALIA |
University of Tokyo | JAPAN |
University of Washington | UNITED STATES |
University of Western Australia | AUSTRALIA |
Utrecht University | NETHERLANDS |
Westfälische Wilhelms-Universität Münster | GERMANY |
Westmead Hospital | AUSTRALIA |
Witten/Herdecke University | GERMANY |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2018 |
Executive EditorBritish Journal of Clinical Pharmacology |
2018 |
MemberPharmacokinetics, United Kingdom |
2018 |
MemberBritish Association for Cancer Research |
2018 |
MemberAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2018 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2017 |
Executive EditorBritish Journal of Clinical Pharmacology |
2017 |
Founding member, Experimental Cancer Medicine Quality Assurance groupCancer Research, Department of Health, United Kingdom |
2017 |
MemberPharmacokinetics, United Kingdom |
2017 |
MemberBritish Association for Cancer Research |
2017 |
MemberAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2017 |
Member, Pharmacogenetics Interest GroupAustralian Society of Clinical and Experimental Pharmacology and Therapeutics |
2017 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2016 |
Executive EditorBritish Journal of Clinical Pharmacology |
2016 |
MemberPharmacokinetics, United Kingdom |
2016 |
MemberBritish Association for Cancer Research |
2016 |
MemberAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2016 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2015 |
Executive EditorBritish Journal of Clinical Pharmacology |
2015 |
MemberPharmacokinetics, United Kingdom |
2015 |
MemberBritish Association for Cancer Research |
2015 |
MemberAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2015 |
Editorial Board MemberClinical Pharmacokinetics |
2014 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2014 |
Executive EditorBritish Journal of Clinical Pharmacology |
2014 |
MemberPharmacokinetics, United Kingdom |
2014 |
MemberBritish Association for Cancer Research |
2014 |
MemberAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2014 |
Member, New Agents GroupNational Cancer Research Institute, United Kingdom |
2014 |
Member, Pharmacology and Molecular Mechanisms groupEuropean Organisation for Research and Treatment of Cancer (EORTC) |
2014 |
Member, Phase I Clinical Trials GroupNewcastle University/Trust |
2014 |
Editorial Board MemberClinical Pharmacokinetics |
2013 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2013 |
Executive EditorBritish Journal of Clinical Pharmacology |
2013 |
MemberLanguage Resources and Evaluation (LREC), Newcastle and North Tyneside |
2013 |
MemberPharmacokinetics, United Kingdom |
2013 |
MemberBritish Association for Cancer Research |
2013 |
Member, New Agents GroupNational Cancer Research Institute, United Kingdom |
2013 |
Member, Pharmacology and Molecular Mechanisms groupEuropean Organisation for Research and Treatment of Cancer (EORTC) |
2013 |
Member, Phase I Clinical Trials GroupNewcastle University/Trust |
2013 |
Editorial Board MemberClinical Pharmacokinetics |
2012 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2012 |
Executive EditorBritish Journal of Clinical Pharmacology |
2012 |
MemberLanguage Resources and Evaluation (LREC), Newcastle and North Tyneside |
2012 |
MemberPharmacokinetics, United Kingdom |
2012 |
MemberBritish Association for Cancer Research |
2012 |
Member, New Agents GroupNational Cancer Research Institute, United Kingdom |
2012 |
Member, Pharmacology and Molecular Mechanisms groupEuropean Organisation for Research and Treatment of Cancer (EORTC) |
2012 |
Member, Phase I Clinical Trials GroupNewcastle University/Trust |
2012 |
Editorial Board MemberClinical Pharmacokinetics |
2011 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2011 |
Executive EditorBritish Journal of Clinical Pharmacology |
2011 |
MemberLanguage Resources and Evaluation (LREC), Newcastle and North Tyneside |
2011 |
MemberPharmacokinetics, United Kingdom |
2011 |
MemberBritish Association for Cancer Research |
2011 |
Member, New Agents GroupNational Cancer Research Institute, United Kingdom |
2011 |
Member, Pharmacology and Molecular Mechanisms groupEuropean Organisation for Research and Treatment of Cancer (EORTC) |
2011 |
Member, Phase I Clinical Trials GroupNewcastle University/Trust |
2011 |
Editorial Board MemberClinical Pharmacokinetics |
2010 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2010 |
MemberLanguage Resources and Evaluation (LREC), Newcastle and North Tyneside |
2010 |
MemberPharmacokinetics, United Kingdom |
2010 |
MemberBritish Association for Cancer Research |
2010 |
Member, New Agents GroupNational Cancer Research Institute, United Kingdom |
2010 |
Member, Pharmacology and Molecular Mechanisms groupEuropean Organisation for Research and Treatment of Cancer (EORTC) |
2010 |
Member, Phase I Clinical Trials GroupNewcastle University/Trust |
2010 |
Editorial Board MemberClinical Pharmacokinetics |
2009 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2009 |
MemberLanguage Resources and Evaluation (LREC), Newcastle and North Tyneside |
2009 |
MemberPharmacokinetics, United Kingdom |
2009 |
MemberBritish Association for Cancer Research |
2009 |
MemberAmerican Association for Cancer Research |
2009 |
Member, New Agents GroupNational Cancer Research Institute, United Kingdom |
2009 |
Member, Pharmacology and Molecular Mechanisms groupEuropean Organisation for Research and Treatment of Cancer (EORTC) |
2009 |
Member, Phase I Clinical Trials GroupNewcastle University/Trust |
2009 |
Editorial Board MemberClinical Pharmacokinetics |
2008 |
Editorial Board MemberCancer Chemotherapy and Pharmacology |
2008 |
MemberLanguage Resources and Evaluation (LREC), Newcastle and North Tyneside |
2008 |
MemberPharmacokinetics, United Kingdom |
2008 |
MemberBritish Association for Cancer Research |
2008 |
MemberAmerican Association for Cancer Research |
2008 |
Member, New Agents GroupNational Cancer Research Institute, United Kingdom |
2008 |
Member, Pharmacology and Molecular Mechanisms groupEuropean Organisation for Research and Treatment of Cancer (EORTC) |
2008 |
Member, Phase I Clinical Trials GroupNewcastle University/Trust |
2008 |